Should You Hold STERIS Stock in Your Portfolio Right Now?

STERIS plc (STE) is demonstrating strong operational performance, with its Healthcare and Applied Sterilization Technologies (AST) segments reporting significant Q1 FY26 revenue growth of 8% and 13% respectively, propelled by service revenues and market adoption. While the company maintains sound financial health, it is contending with macroeconomic headwinds, adverse currency fluctuations, and rising costs from tariffs and inflation, which have contributed to its shares underperforming industry benchmarks and the S&P 500 over the past year. Despite these pressures, analysts forecast an improvement in fiscal 2026 earnings and revenue, suggesting potential rebound prospects.

Analysis

STERIS plc is demonstrating robust operational performance, particularly within its core segments, yet faces significant macroeconomic headwinds that have suppressed its stock performance. The Healthcare segment's revenue grew 8% year-over-year in the first quarter of fiscal 2026, driven by a 13% increase in service revenues and solid growth in both consumables and capital equipment, with a strong forward indicator in its 14% order growth. Concurrently, the Applied Sterilization Technologies (AST) segment expanded by 13%, fueled by a 12% rise in service revenues from bioprocessing and medical device clients. This operational strength is supported by a solid balance sheet, evidenced by a reduction in long-term debt and a total debt-to-capital ratio of 21.4%. Despite these fundamentals and a positive earnings yield of 4.20% against a negative industry average, the company's stock has underperformed, rising only 4.8% in the past year compared to the S&P 500's 18.4% gain. This lag is attributable to noted risks including cost pressures from tariffs and raw materials, adverse currency fluctuations impacting its substantial international business (nearly 30% of revenue), and broader macroeconomic volatility. However, analyst consensus for fiscal 2026 remains positive, projecting 9.1% EPS growth and 8.2% revenue growth, suggesting a conflict between current market sentiment and underlying business momentum.

Key Decisions for Investors

• Given the disconnect between strong segment growth (Healthcare +8%, AST +13%) and recent stock underperformance, investors may consider the current valuation a potential entry point, assuming a tolerance for the cited macroeconomic and currency risks.
• It is crucial to monitor indicators of raw material costs and the impact of tariffs in upcoming earnings reports, as these factors are identified as the primary drags on profitability and share price.
• Investors should weigh STE's solid earnings yield and balance sheet against its stock's lag and consider a relative value analysis against the 'better-ranked' peers mentioned (MASI, PAHC, CAH) which have demonstrated stronger share price momentum.
• Closely track foreign exchange rate movements, especially in key non-U.S. markets, as currency fluctuations are a material risk factor with nearly 30% of revenues generated outside the United States.